Want to learn more? We’d love to hear from you. US Headquarters 9605 Medical Center Dr. Suite 270 Rockville, MD 20850 European Office Theriva™ Biologics SL Carrer Torrent de Can Ninou, naus 5-6 08150 – Parets del Vallès (Barcelona) Spain Email info@therivabio.com
November 03, 2022 08:00 ET – Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee – – Cohort 2 Patient Dosing Highlights Momentum Across the Theriva Oncology-Focused Clinical Pipeline – ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva
September 27, 2022 08:00 ET – The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 – ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for
ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D
ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share
Synthetic Biologics Announces Reverse Stock Split Read More »
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind
